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Background: Dietary oleic acid may prevent pancreatic ductal adenocarcinoma 
(PDA) by reducing hyperinsulinaemia which can otherwise promote DNA damage 
and tumour growth. Results from previous epidemiological studies investigating oleic 
acid are inconsistent. This study aims to clarify the relationship between dietary oleic 
acid intake and the risk of developing PDA using nutritional information from food 
diaries plus published serum biomarker data from HbA1c. 
Methods: 23,658 participants, aged 40-74 years, were recruited into EPIC-Norfolk 
and completed 7-day food diaries which recorded; foods, brands and portion sizes to 
calculate nutrient intakes. Serum HbA1c was measured at recruitment in 11,147 
participants (48.7% of cohort). Hazard ratios (HRs) for quintiles of dietary oleic acid 
intake and serum HbA1cwere estimated using Cox regression. Additional analyses 
were made according to whether body mass index (BMI) was greater or less than 
25kg/m2 as this influences hyperinsulinaemia 
Results: 88 participants (55% women) developed PDA after a mean follow-up of 8.4 
years (SD=3.9) (mean age at diagnosis=72.6 years, SD=8.8). A decreased risk of 
PDA was associated with increased dietary oleic acid intake (highest vs lowest 
quintile, HR=0.29, 95% CI=0.10-0.81, P trend across quintiles=0.011), with statistical  
significance maintained when BMI>25kg/m2 but not if BMI<25kg/m2. An elevated 
serum HbA1c was associated with increased risk of disease (highest vs lowest 
quintiles, HR=6.32, 95% CI=1.38-28.89, P for trend=0.004). 
Conclusions: The data supports a protective role of oleic acid against development 
of PDA in those with higher BMIs possibly through influencing hyperinsulinaemia. 









Worldwide, pancreatic ductal adenocarcinoma (PDA) causes more than a 
quarter of a million deaths each year and is the 8th commonest cause of cancer 
death.1 Less than 3% of patients survive more than 5 years with only minimal 
improvements in survival over recent decades.2, 3 An improved understanding of the 
aetiology of pancreatic cancer would inform recommendations to reduce the risk of 
disease in the population. Positive risk factors for PDA include: a family history of this 
cancer,4 cigarette smoking5 and chronic pancreatitis.6 Epidemiological studies also 
report an increased risk with elevated serum glucose,7, 8 type 2 diabetes9 and an 
increased body mass index10 with hyperinsulinaemia a potential underlying 
mechanism for these associations. Hyperinsulinaemia may induce carcinogenesis via 
several mechanisms including oxidative stress11 inducing damage to DNA,12 directly 
stimulating cancer cell growth,13, 14 and promoting tumour invasion.15 
Hyperinsulinaemia may be particularly relevant to pancreatic carcinogenesis as 
insulin is secreted by the pancreas and therefore present locally at high 
concentrations.16 
Reducing insulin levels through lifestyle measures including dietary ones 
could lower the risk of developing PDA. The nutrient oleic acid is a n-9 
monounsaturated fatty acid that is naturally found in greater quantities than any other 
fatty acid. It is present in both animal and vegetable oils, especially olive and 
rapeseed oils. Oleic acid can reduce insulin secretion and increase sensitivity17-19 
with actions in skeletal muscle cells effected through mitochondrial beta-oxidation 
mediated by PPAR alpha and protein kinase A-dependent mechanisms.20 Oleic acid 
also influences the effects of the inflammatory cytokine TNF-alpha on insulin 
production.17 Furthermore, increasing body mass index (BMI) is directly related to 
increased insulin secretion and insulin resistance,21 with increased BMI recognised 
as a positive risk factor for developing PDA.22-24 A mechanistic role for oleic acid 
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would be supported if its effects are more profound in those with increased body 
mass index. 
To support an aetiological role for oleic acid in preventing PDA, 
epidemiological studies are required investigating dietary oleic acid intake and the 
risk of developing PDA. However, two US (United States) cohort studies reported no 
associations.25, 26 Case-control studies reported both inverse27and positive 
associations.28 The inconsistencies in these results may be due to inaccuracies in 
measuring diet which may make any true differences difficult to detect although the 
methods of recording dietary intake vary. All previous aetiological studies have used 
food frequency questionnaires (FFQs), where subjects recorded the frequency of 
consumption of standard portion sizes of selected listed food items. FFQs are quicker 
to complete than 7-day food diaries (7-DFDs) but are less accurate.29 The baseline 
measurement of nutrient intake has been demonstrated to be an accurate at ranking 
an individual over a five year period.30 
The aim of this work was to conduct, for the first time, a prospective cohort 
study of dietary oleic acid intake in the aetiology of pancreatic cancer using nutritional 
data derived from 7-day food diaries (7-DFDs). We sought to provide mechanistic 
data using glycosylated haemoglobin (HbA1c) a marker of insulin resistance. Oleic 
acid in reducing insulin resistance would lead to decreased levels of HbA1c and an 
associated reduction in the risk of PDA. Consistent dietary and biomarker results 
would support a role for a decreased oleic acid intake along with hyperinsulinaemia 
in the aetiology of PDA and suggest dietary measures to reduce cancer risk. 
 
 
Materials and Methods 
The cohort was 23 658 men and women, aged 40 to 74 years, who were 
recruited into the European Prospective Investigation of Cancer-Norfolk Study (EPIC-
Norfolk) and completed 7-day food diaries, between the years 1993 and 1997. 
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Participants were resident in the county of Norfolk, United Kingdom, registered in 35 
general practices in rural, suburban and inner city areas. The Norwich District Health 
Authority Ethics Committee approved the study. All participants gave signed consent 
for their medical notes to be reviewed in the future. At recruitment, participants 
completed detailed questionnaires on their: demography, previous medical history, 
medication, habitual diet and smoking. Participants attended a baseline health check, 
supervised by a nurse,31 who explained the completion of the 7-day food diary (7-
DFD), the first day of which was recorded with the nurse, as a 24 hour recall of the 
participant’s previous day’s dietary intake. The remaining six days were completed by 
participants themselves at home, who recorded their entire dietary intake, including: 
food types, portion sizes, brands, cooking methods and recipes in eight separate 
meal times each day. The names of commercially prepared foods or packaging from 
products consumed were recorded in the diary to allow more accurate nutritional 
assessments. Portion sizes were estimated by participants by either weighing their 
food or comparing it with supplied photographs of varying portion sizes. After 
completion the 7-DFDs were returned to the study headquarters where they were 
coded by a nutritionist, with the data inputted into a specially designed computer 
programme called DINER (Data In to Nutrients for Epidemiological Research). Each 
entry in the diary was matched to one of 11 000 food items and 55 000 portion sizes 
within DINER, by selecting the food item which best described it. Where descriptions 
were lacking the item was assigned the average composition for that food type. 
DINER facilitated the translation from participant reported free text of food to 
structured data which could then be electronically converted into nutrient values or 
food groups(11). The DINER nutrient database is based on foods in the United 
Kingdom Food Composition Database, the nutrient database of the Royal Society of 
Chemistry and from food manufacturers’ databases. Each 7-DFD took approximately 
4 hours to code with an average of 220 individual food and drink items reported by 
participants in their diaries. An example of the detail of this method was that 337 
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specific types and brands of breakfast cereals were included in DINER. The 
computer program checked for potential errors in the coded diaries such as 
unexpectedly large portion sizes or duplication and any anomalies were checked by 
the nutritionists. A total of 11 112 of the total cohort (47.0%), that were recruited after 
November 1995, underwent venepuncture for a sample of EDTA-anticoagulated 
blood which was used to measure HbA1c. The blood was stored at 4–7°C until it was 
transported for HbA1c assay by high-performance liquid chromatography on a Bio-
Rad Diamat. 
Following recruitment, the cohort was monitored for 17 years, up to June 
2010, to identify those initially well participants who later developed incident 
pancreatic cancer. Cases were identified by matching the EPIC-Norfolk database 
with: firstly the Norfolk Health Authority records of hospital admissions and secondly 
the Eastern Cancer Registry and Information Centre (ECRIC).  The notes of all 
potential cases were reviewed by a medical gastroenterologist (PJRB) to verify the 
diagnoses and the clinical staging as classified by the American Joint Committee on 
Cancer.32 Information was also obtained on the confirmatory investigations, treatment 
received and survival time following diagnosis.  Cases were excluded if there was 
diagnostic uncertainty, participants had pancreatic cancer prior to enrolment or if the 
diagnosis was made within 12 months of entering the study. 
A case-cohort analysis was performed between cases and a random sample 
of 3 970 food diaries from controls that had had their food diaries coded. A case-
cohort analysis compares those in a cohort who develop disease against controls 
selected from the parent cohort without using matching criteria. This method of 
analysis was used as not all of the diaries of the 23 658 participants are coded. 
Baseline characteristics were compared between participants with and without 
incident pancreatic cancer using a t-test for normally distributed continuous variables 
and a chi-squared test for categorical ones. Oleic acid intakes and serum HbA1c 
were divided into quintiles across the distribution of the whole cohort. The primary 
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outcomes were Hazard ratios, estimated using Cox proportional hazard regression 
models, with 95% confidence intervals, of developing pancreatic cancer for each 
quintile of oleic acid intake, using the lowest one as the reference. All analyses were 
adjusted for the co-variates of age at recruitment and gender, with additional models 
including cigarette smoking status (never, previous or current) and type 2 diabetes at 
baseline (yes/no) and total energy intake. No adjustments were made for body mass 
index as it is related to energy intake and may act via the same mechanistic pathway; 
i.e. via hyperinsulinaemia. To provide mechanistic information that oleic acid may 
prevent PDA through reducing hyperinsulinaemia, analyses were conducted in 
participants with a BMI greater than and less than 25kg/m2.  Support for such a 
mechanism would be suggested by inverse associations with oleic acid this group but 
not in those less likely to have increased insulin i.e. those with a BMI<25kg/m2. No 
adjustment was made for serum HbA1c as it too is likely to be part of the same 
causal pathway. For all analyses a further calculation was made excluding those 
diagnosed within 5 years of recruitment to reduce the risk of a protopathic bias 
(undiagnosed disease influencing results) and ensure that the data was truly 




In the cohort of 23 658 participants (55% were female) who attended the baseline 
health check and completed a 7-day food diary, 88 (0.37%) participants developed 
pancreatic cancer during the 17 year follow up period of which 48 cases (55% of 
cases) were female. The mean time between recruitment and diagnosis was 8.4 
years (SD=3.9 years). At diagnosis 14.9% had disease localised to the pancreas, 
30.1% locally advanced disease, 46.6% had metastatic disease with no staging 
available on 8.0%. Histological confirmation was available in 35%. The treatments 
received were: surgery (8%), chemotherapy (35%) and solely palliative measures 
(57%). The median survival after diagnosis was 4.0 months (range 0.5-25 months). 
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For patients where histology was not sought, a diagnosis of pancreatic cancer was 
made via at least two radiological modalities which demonstrated typical findings of 
the disease. The clinical characteristics of the patients with and without histology 
were similar; namely local or metastatic spread (78% vs 74%, p=0.65) and median 
survival (3 vs 4 months, p=0.73). The characteristics of the subcohort of controls 
used in this analysis were almost identical to the demographics of other controls in 
the whole cohort, whose food diary data was not available (age at recruitment 59.3 
yrs in subcohort vs 59.0 yrs in whole cohort and gender was 43.8% men in subcohort 
vs 45.5% men in whole cohort). The average daily intake of oleic acid was 
significantly lower in cases (16.9 grams per day) compared to controls (18.7 grams 
per day) (table 1). Serum HbA1c was higher in cases (39.1 mmol/mol) compared to 
controls (34.6 mmol/mol). 
In the analysis of dietary oleic acid intake there were statistically significant 
inverse association for the risk of developing pancreatic cancer for each of the three 
higher quintiles of intake (highest vs lowest quintile HR=0.29 (95% CI=0.10-0.81). 
Importantly, there was also a significant trend across categories (HR=0.72, 95% CI 
0.56-0.93, p=0.011) (Table 2). After excluding participants diagnosed within 5 years 
of enrolment, all four higher quintiles of intake had significant inverse associations 
(highest vs lowest quintile HR=0.16 (95% CI=0.05-0.52)) with a significant trend 
across quintiles (HR=0.65 95% 0.48-0.86, p=0.003) (table 2). Excluding participants 
with known diabetes at recruitment did not alter the magnitude of the associations. In 
the model containing only age and gender the results were similar, but with smaller 
effect sizes. Analysing dietary oleic acid intake by BMI, identified those with a BMI 
greater than 25kg/m2 (whose participants are more likely to have a hyperinsulinaemic 
state), had a significant trend across quintiles HR=0.67 (95% CI 0.47-0.95, p=0.022). 
In those with a BMI<25kg/m2 no effects were seen although the hazard ratios for an 
increased oleic acid intake suggested a negative association (trend across quintiles 
HR=0.78 95% CI 0.54-1.13, p=0.19).The small numbers of participants with prevalent 
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diabetes (125 participants including 4 cases) prevented undertaking a meaningful 
sensitivity analysis according to diabetes status at baseline. 
In the biomarker analysis of HbA1c, 35 cases of PDA had donated serum (39.8% 
of the total cases). All higher quintiles of HbA1c were associated with at least a 
doubling of the risk of developing PDA, with the highest quintile reaching statistically 
significance (HR=6.32, 95% CI=1.38-28.89), with a trend across quintiles (HR=1.52, 
95% CI 1.15-2.03,p=0.003)(table 2). For cases diagnosed after 5 years of 
recruitment (n=26), the magnitude of the effect sizes were increased (highest vs 
lowest quintile, HR=8.79 95% 1.09-71.04), with a trend across quintiles HR=1.63 
(95%CI 1.14-2.33, p=0.006). Excluding participants with diabetes at recruitment did 
not significantly alter the HbA1c results (highest vs lowest quintile HR=6.20, 95% 
CI=1.35-28.40, p=0.004).  
 
Discussion 
The main finding of this study was that an increased dietary oleic acid intake 
was inversely associated with the development of PDA. Evidence for a causal 
protective effect of oleic acid is suggested by the plausible biological mechanisms, 
large effect sizes, a biological gradient, adjustment for covariates and temporal 
collection of the nutrient data. The highest intake of oleic acid was associated with an 
84% reduction in risk after excluding those diagnosed within 5 years. To achieve the 
highest quintile of intake, participants would have consumed at least 23.7 grams per 
day of oleic acid which equates to 34 grams (two tablespoons) of olive oil per day.  
Oleic acid increases insulin sensitivity in animal models,17 patients with type 2 
diabetes,18 adult populations19 and in studies of volunteers randomised to diets rich in 
oleic acid.33 Excess insulin may promote carcinogenesis by increasing pro-
inflammatory cytokine production, including interleukin-6, tumour necrosis factor-α 
and C-reactive protein.34 These stimulate the formation of reactive oxygen species 
which can induce mutations in key oncogenes and tumour suppressor genes.12 
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Furthermore, insulin directly induces tumour growth, in a dose-dependent effect on 
pancreatic cancer cell lines in-vitro.35 Excess insulin is particularly relevant to PDA as 
there is a 20-fold higher concentration of insulin in the pancreas than in the systemic 
circulation and hence its local mitotic effect could be profound.16 Oleic acid may lower 
insulin levels which reduces the risk of developing PDA. This is supported by our 
findings, firstly; that increased dietary oleic acid had a stronger association in 
participants with a higher BMI (which is associated with hyperinsulinaemia) and 
secondly; there was an 8-fold increased risk with elevated serum HbA1c (a marker of 
hyperinsulinaemia) including in those without diabetes at enrolment. The lack of a 
statistical effect of oleic acid intake in those with a BMI<25 could be explained by two 
potential mechanism. Firstly; a reduction in case numbers (dropping from 88 to 41) 
preventing the detection of an association (type 2 error). Secondly; that oleic acid has 
less of an impact on those with a low BMI as this population will have lower insulin 
levels and hence not benefit from further insulin modification. 
 Two previous cohort studies have also reported positive associations of 
HbA1C with pancreatic cancer.36, 37 The stronger associations with PDA noted after 
excluding those diagnosed within 5 years of enrolment suggest that pancreatic 
carcinogenesis occurs over a prolonged period which could reflect the evolution of 
pancreatic intraepithelial neoplasia (PanINs). 
To confirm that dietary oleic acid has a causal role in preventing pancreatic 
cancer supportive data from many epidemiological studies is required, ideally from 
prospective cohort investigations or randomised controlled trials of oleic acid 
supplementation in the general population. To the best of our knowledge, there are 
just two prospective cohort investigations, although these used nutritional information 
reported in food frequency questionnaires rather than more accurate7-DFDs. The US 
Nurses’ Health Study and the NIH-AARP study both reported no differences between 
the highest and lowest quintiles of oleic acid intake and no trends across 
categories.25, 26 A case-control study from Canada of 462 cases of pancreatic cancer 
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and 4721 controls, documented dietary oleic acid was associated with a non-
significant reduced risk of pancreatic cancer (highest vs lowest intake OR=0.75, 95% 
CI=0.55-1.02). As in our work, a stronger inverse association was found in 
participants with an increased BMI (BMI>30kg/m2highest quartile, odds ratio=0.36, 
95% CI 0.19-0.72, P-trend=0.002) and no effect in those with a BMI<25kg/m2.27 The 
Canadian retrospective study also reported several fatty acid groups were associated 
with a decreased odds, including saturated and MUFAs, which could represent a 
correlated effect of nutrients or recall bias in cases for pre-symptomatic diet. A case-
control study from San Francisco with 532 cases of PDA reported oleic acid was 
associated with an increased risk of disease (highest vs. lowest quartile, OR=1.4, 
95% CI=1.1-1.9, P-trend=0.008).28 The inconsistencies in these results from 
epidemiological studies may be due to measurement error for diet and biases 
inherent in retrospective work which may make any true differences difficult to detect. 
All these previous studies used food frequency questionnaires (FFQs) to measure 
habitual diet, where subjects record the frequency of consumption of standard portion 
sizes of selected listed food items. FFQs, although quicker to complete are less 
accurate than detailed seven day food diaries (7-DFDs).29 For example, using 16 day 
weighed records as the standard, the correlation coefficients from 7-DFDs for fat 
intake were 0.63 compared with those from FFQs of 0.55 and for sugar intake the 
correlation coefficients were 0.77 and 0.51 respectively.29 Our study is the first cohort 
investigation to use the more accurate 7-DFDs to assess oleic acid in the aetiology of 
pancreatic cancer. 
Our work has several methodological strengths including the minimisation of 
biases associated with case-control investigations including selection bias and recall 
bias for diet. The case ascertainment was accurate as all potential case notes of 
PDA were reviewed by a clinical gastroenterologist to confirm the diagnosis. Follow-
up bias was minimised by identifying cases from two comprehensive sources; 
namely hospital records and regional cancer registry data. Furthermore, twenty years 
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after recruitment commenced 94.6% of participants still lived in Norfolk. By analysing 
exposures in those diagnosed after more than 5 years of enrolment this further 
reduces any potential effect of recall bias or alteration of biomarkers by the pre-
symptomatic cancer. Although the study was conducted in just one county in 
England, the cohort was generalisable in terms of: demography, incidence and the 
clinical characteristics of PDA.1 The intake of dietary oleic acid in this study was 
similar to other work. Our top quintile range of oleic acid intake was 23.7 to 78.4 
grams/day with the Canadian case-control reporting the highest quartile median 
intake of 28.4grams per day.27 The San Francisco case-control study recorded the 
highest quartile intake of oleic acid was greater than 25grams per day.28 Several risk 
factors for PDA were included in the analyses, namely smoking and diabetes. No 
adjustment was made for BMI as it is on the same causal pathway as oleic acid and 
furthermore energy intake was considered, which is positively associated with BMI. 
There were several methodological limitations of this study including the small 
numbers which reduced the precision of several estimates although the effect sizes 
were large enough to detect with this sample size. In the future, we will continue case 
ascertainment in the cohort to obtain more precision of the estimates. 
  Changes can occur in participants’ diet between recruitment and over time 
and with seasonal variation, although these will occur in both those who become 
cases and those who become controls. This form of measurement error, regression 
dilution bias, will result in a spurious under-estimate of the true effect size rather than 
an inaccurate over-estimate. A single baseline measurement of diet has been 
demonstrated to rank subjects according to their nutrient intake with a decline of 
correlation coefficients of only 0.07 over 5 years30 which allows a reasonable 
comparison to be made of nutrient intake between subjects to be made over a 
prolonged period. In our study, the maximum follow up interval to diagnosis was 17 
years, although the mean time to diagnosis was 8.4 years with a standard deviation 
of 3.9 yrs. Pancreatic carcinogenesis could be influenced by environmental factors 
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over a prolonged period, with the precursor lesions for pancreatic cancer, “PanINs”, 
common in later life, although only a small percentage progress from low grade to 
high grade lesions associated with invasive disease.38 
A potential weakness was that histological confirmation of pancreatic cancer 
was obtained in only 35% of the cases. This was due to the lack of tissue sampling 
techniques in the 1990’s, such as endoscopic ultrasound and fine needle aspiration, 
which only became available later. However, the clinical characteristics between 
cases with and without histology were similar so this is unlikely to have introduced 
significant error. A further weakness is the case-cohort method of analysis rather 
than a full cohort analysis, although the use of nearly four thousand non-cases in this 
study is expected to produce very similar results to analysis against the whole cohort 
of 23 658 participants. In the future, the EPIC study aims to code all participant’s 
diaries when the data can be reanalysed. 
In conclusion, this prospective cohort study reported, for the first time, large 
inverse associations between oleic acid intake, in a dose-dependent manner, and the 
risk of pancreatic cancer. There are plausible biological mechanism for this 
association including oleic acid increasing insulin sensitivity, which is supported by 
firstly our data on the positive association with serum HbA1c and secondly, oleic acid 
reducing the risk in those with higher BMIs, both of which are associated with 
hyperinsulinaemia. Future observational studies need to confirm this association to 
imply causality, preferably in prospective cohort studies using dietary information 
derived from food diaries. If the findings are consistent, increased oleic acid 
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